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A B S T R A C T 
Objective: To report the outcomes of more than 
100 cycles of preimplantation genetic diagnosis for 
monogenetic diseases.
Design: Case series.
Setting: Tertiary assisted reproductive centre in 
Hong Kong, where patients needed to pay for the 
cost of preimplantation genetic diagnosis on top of 
standard in-vitro fertilisation charges. 
Patients: Patients undergoing preimplantation 
genetic diagnosis for monogenetic diseases at the 
Centre of Assisted Reproduction and Embryology, 
Queen Mary Hospital–The University of Hong Kong 
between 1 August 2007 and 30 April 2014 were 
included.
Interventions: In-vitro fertilisation, intracyto-
plasmic sperm injection, embryo biopsy, and 
preimplantation genetic diagnosis.
Main outcome measures: Ongoing pregnancy rate 
and implantation rate.
Results: Overall, 124 cycles of preimplantation 
genetic diagnosis were initiated in 76 patients, 
101 cycles proceeded to preimplantation genetic 
diagnosis, and 92 cycles had embryo transfer. The 
ongoing pregnancy rate was 28.2% per initiated 
cycle and 38.0% per embryo transfer, giving an 
implantation rate of 35.2%. There were 16 frozen-
thawed embryo transfer cycles in which, following 
Experience of more than 100 preimplantation 
genetic diagnosis cycles for monogenetic diseases 
using whole genome amplification and linkage 
analysis in a single centre
Introduction
Preimplantation genetic diagnosis (PGD) refers to 
the determination of genotype of embryos before 
transfer during in-vitro fertilisation (IVF) cycles. The 
technique can prevent couples at risk for a serious 
genetic disease from having an affected fetus, and 
therefore protects couples from the psychological 
trauma associated with carrying an affected child, 
termination of pregnancy, or recurrent miscarriage. 
New knowledge added by this study
• Preimplantation genetic diagnosis is feasible and reliable for at least 20 genetic conditions in Hong Kong.
Implications for clinical practice or policy
• Preimplantation genetic diagnosis should be considered an alternative method in preconception counselling for 
couples at risk for a serious genetic disease.
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During PGD, one blastomere is biopsied from each 
day-3 embryo (6-8 cells) and, after whole genome 
amplification (WGA), mutations can be detected 
directly by minisequencing and/or indirectly by 
linkage analysis. The first PGD baby was born in 
1989 following PGD for a sex-linked genetic disease 
using polymerase chain reaction (PCR) for sex 
determination.1 
 According to a recent report of the European 
ORIGINAL ARTICLE
preimplantation genetic diagnosis, cryopreserved 
embryos were replaced resulting in an ongoing 
pregnancy rate of 37.5% and implantation rate 
of 30.0%. The cumulative ongoing pregnancy 
rate was 33.1%. The most frequent indication for 
preimplantation genetic diagnosis was thalassaemia, 
followed by neurodegenerative disorder and cancer 
predisposition. There was no misdiagnosis.
Conclusions: Preimplantation genetic diagnosis 
is a reliable method to prevent couples conceiving 
fetuses severely affected by known genetic disorders, 
with ongoing pregnancy and implantation rates 
similar to those for in-vitro fertilisation for routine 
infertility treatment.
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利用全基因組擴增和連鎖分析為單基因疾病進行
逾百個胚胎植入前遺傳學診斷週期
鄒鳳翔、楊樹標、李芷茵、劉綺蘭、何柏松、吳鴻裕
目的：報告逾百個胚胎植入前遺傳學診斷（PGD）在單基因疾病週期
的結果。
設計：病例系列研究。
安排：香港一所設有體外受精以及PGD收費服務的大學醫院輔助生育
中心。
患者：2007年8月1日至2014年4月30日期間，在香港大學瑪麗醫院輔
助生育中心對單基因疾病進行PGD的患者。
介入：體外受精（IVF）、卵胞漿內單精子注射（ICSI）、胚胎活檢
和PGD。
主要結果測量：持續妊娠率及著床率。
結果：研究期間76位婦女為PGD進行了124個週期的超排卵，其中
101例成功進行PGD，92例進行了胚胎移植。持續妊娠率為每超排卵
週期28.2%，及每移植週期38.0%，著床率為35.2%。經PGD診斷為正
常的胚胎，經過凍存後進行了16次凍融胚胎移植週期，持續妊娠率為
37.5%，著床率30.0%。累計持續妊娠率為每超卵排週期33.1%。最常
見進行PGD的單基因疾病是地中海貧血、神經退化性疾病和癌症的易
感性。至今沒有誤診。
結論：PGD是一種可靠的方法，以避免夫婦懷有受嚴重遺傳病影響的
胎兒。經過PGD篩選後的持續妊娠率及著床率跟那些接受常規IVF治
療不孕症的週期相若。
Society of Human Reproduction and Embryology 
(ESHRE) PGD Consortium,2 there were more 
than 4500 PGD cycles performed for monogenetic 
diseases worldwide in 2002 to 2012. The Centre of 
Assisted Reproduction and Embryology, Queen 
Mary Hospital–The University of Hong Kong (HKU-
QMH CARE) achieved the first live birth after PGD 
for alpha-thalassaemia in 2005.3 Due to the very 
limited amount of DNA available for diagnosis in a 
single cell, the major technical challenge of PGD is 
contamination and allele dropout, which may result 
in misdiagnosis. In August 2007, we adopted the 
platform of WGA for PGD. Such WGA amplifies 
a major portion of the genome of single cells with 
good reproducibility,4 and enables direct mutation 
detection and linkage analysis simultaneously for 
accurate determination of the genotype of embryos. 
We reported our first live birth after PGD for 
Huntington’s disease (HD) using WGA in 2009.5 We 
now report the outcome of over 100 PGD cycles for 
monogenetic diseases at the HKU-QMH CARE.
Methods
Study population
Data from all treatment cycles were stored in a 
database and PGD cases were coded for indication. 
The data of all PGD cycles for monogenetic diseases 
performed in the Department of Obstetrics and 
Gynaecology, Queen Mary Hospital/The University 
of Hong Kong from 1 August 2007 to 30 April 2014 
were retrieved. Depending on the monogenetic 
disease, the definitive mutation(s) responsible 
for the disease were confirmed in accredited 
genetic laboratories, including the Department of 
Pathology, Queen Mary Hospital; Clinical Genetic 
Service, Department of Health, Hong Kong SAR; 
and Molecular Pathology Division, Hong Kong 
Sanatorium & Hospital. Preimplantation genetic 
diagnosis was offered to couples with a defined 
genetic disease, irrespective of whether the couples 
had a previous affected pregnancy. All couples 
were extensively counselled by the reproductive 
medicine subspecialists and a clinical geneticist on 
the potential risks of IVF, intracytoplasmic sperm 
injection (ICSI), and PGD. The couples decided 
whether to proceed to PGD after non-directive 
informative counselling. They were also advised 
to have a confirmatory prenatal diagnosis for the 
ensuing pregnancy. Depending on the availability 
of the test, couples could choose an invasive or 
non-invasive prenatal diagnostic test to confirm 
the diagnosis by an accredited genetic laboratory 
different from the PGD laboratory.
Treatment regimen
The details of the protocols for the ovarian 
stimulation regimen, gamete handling, and frozen-
thawed embryo transfer (FET) have been previously 
described.6 Surplus good-quality embryos unaffected 
by monogenetic diseases were vitrified by the 
CVM Vitrification System (CryoLogic, Mulgrave, 
Australia). If the patient did not become pregnant in 
the fresh cycle, the vitrified embryos were warmed 
and replaced in a subsequent FET cycle.
Preimplantation genetic diagnosis
The HKU-QMH CARE has been performing PGD for 
about 10 years. The procedures for PGD have been 
previously described.5 In brief, embryo biopsy was 
performed on day 3 at the 6 to 8 cells stage, with one 
blastomere biopsied. Whole genome amplification 
by multiple displacement amplification was 
performed on a single blastomere.5 In all the PGD 
cases for monogenetic diseases, apart from direct 
mutation detection (except for those involving large 
deletions), linkage analysis was performed by two 
to 10 microsatellite markers flanking the mutation 
to reduce possible errors due to allelic dropout. 
Aneuploidy was not determined because of lack 
of indications. When required, human leukocyte 
antigen (HLA) typing was performed by PCR-based 
sequence specific primer (Collaborative Transplant 
Study, University of Heidelberg, Heidelberg, 
Germany) in the same setting as for PGD.
#  Preimplantation genetic diagnosis for monogenetic disease  # 
301Hong Kong Med J  ⎥  Volume 21 Number 4  ⎥  August 2015  ⎥  www.hkmj.org
Results
Between 1 August 2007 and 30 April 2014, 76 couples 
initiated 124 cycles for monogenetic diseases. The 
median age of the women was 35 (range, 26-41) 
years. Embryo biopsy and PGD were performed in 
101 cycles, including three cycles of combined HLA 
typing and beta-thalassaemia. The mean number 
of embryos biopsied per oocyte retrieval cycle 
was 6.1 (761/124). A total of 761 blastomeres were 
biopsied and a conclusive diagnosis was obtained for 
692 (91%) blastomeres. An inconclusive diagnosis 
during PGD could be due to failure in WGA or 
aneuploidy. Preimplantation genetic diagnosis was 
cancelled in 23 (18.5%) cycles after initiation of 
stimulation because of poor responses (13 cycles), 
risk for ovarian hyperstimulation syndrome (OHSS; 
4 cycles), no mature oocytes available (3 cycles), 
failed fertilisation (2 cycles), or an embryologist 
was unavailable for PGD (1 cycle). In case of poor 
response (<4 good-quality embryos on day 3), 
cleavage-stage embryos were frozen, subsequently 
thawed, and pooled with fresh embryos from the 
following stimulated cycle for PGD. When there 
was excessive ovarian response and a patient was 
at risk for OHSS, all cleavage-stage embryos were 
cryopreserved and PGD was performed in the 
hormone replacement treatment cycles. 
 Overall, 92 PGD cycles proceeded to embryo 
transfer with one or two blastocysts replaced 
(mean, 1.8), resulting in an ongoing pregnancy 
rate (pregnancy beyond 8-10 weeks of gestation) 
of 28.2% per initiated cycle, 38.0% per transfer, and 
implantation rate of 35.2% (Table 1). Embryo transfer 
was cancelled in nine (8.9%) cycles after PGD due 
to no genetically transferrable embryos available 
(4 cycles), no HLA-matched embryo (1 cycle), or 
patient at risk for OHSS (4 cycles). From August 
2012 onwards, all genetically transferrable embryos 
were cryopreserved after PGD when patients were at 
risk for OHSS. 
 There were 16 cycles of natural-cycle FET for 
PGD blastocysts, resulting in an ongoing pregnancy 
rate of 37.5% per transfer. The mean number of 
blastocysts replaced in the FET cycle was 1.3. The 
implantation rate in the FET cycle was 30.0%. The 
cumulative ongoing pregnancy rate was 33.1% per 
initiated cycle (Table 1).
 The indications for PGD are listed in Table 
2. The most frequent indication for PGD was 
thalassaemia (70.2%), followed by spinocerebellar 
ataxia type 3 (SCA3; 4.8%), and HD (4.0%). 
Preimplantation genetic diagnosis was performed 
for 20 monogenetic diseases. Successful pregnancy 
was achieved after PGD for 14 genetic diseases. The 
pregnant women were referred to the maternal-fetal 
medicine team at Tsan Yuk Hospital for counselling 
and confirmation of the genetic diseases by prenatal 
diagnosis or postnatal cord blood genetic tests. 
TABLE 1.  Results of preimplantation genetic diagnosis in fresh and frozen-thawed 
embryo transfer cycles
Fresh ET Frozen-thawed ET
No. of initiated cycles 124 -
No. of PGD performed 101 -
No. of ET 92 16
Mean No. of embryos replaced per ET 1.8 1.3
OPR per initiated cycle 28.2% -
OPR per ET 38.0% 37.5%
Implantation rate 35.2% 30.0%
Cumulative OPR per initiated cycle 33.1%
Abbreviations: ET = embryo transfer ; OPR = ongoing pregnancy rate (pregnancy 
beyond 8-10 weeks of gestation); PGD = preimplantation genetic diagnosis
TABLE 2.  List of preimplantation genetic diagnosis cycles for monogenetic diseases
No. of 
cycles
Mode of 
inheritance
Live birth
Blood disorder
Haemophilia A 1 X-linked recessive No
Alpha-thalassaemia 64 Autosomal recessive Yes
Beta-thalassaemia ± HLA 23 Autosomal recessive Yes
Neurodegenerative disorder
Huntington’s disease 5 Autosomal dominant Yes
Spinocerebellar ataxia type 3 6 Autosomal dominant Yes
Cancer predisposition
Breast cancer (BRCA2) 1 Autosomal dominant Yes
Familial adenomatous polyposis 2 Autosomal dominant Yes
Neurofibromatosis type I 1 Autosomal dominant Yes
Pheochromocytoma 1 Autosomal dominant No
von Hippel–Lindau disease 1 Autosomal dominant No
Muscular dystrophy
BMD/DMD 3 X-linked recessive Yes
Myotonic dystrophy 2 Autosomal dominant No
Connective tissue/skeletal disorder
Osteogenesis imperfecta 3 Autosomal dominant No
Spondyloperipheral dysplasia 1 Autosomal dominant Yes
Metabolic disorder
Metachromatic leukodystrophy 1 Autosomal recessive Yes
Propionic acidaemia 1 Autosomal recessive Yes
Others
Juvenile retinoschisis 1 X-linked recessive Yes
Opitz G/BBB syndrome 1 X-linked recessive No
Synpolydactyly 3 Autosomal dominant Yes
Tuberous sclerosis 2 Autosomal dominant Yes
Waardenburg syndrome type I 1 Autosomal dominant No
Abbreviations: BMD = Becker muscular dystrophy; DMD = Duchenne muscular 
dystrophy; HLA = human leukocyte antigen
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The latter was chosen by some of the patients who 
worried about the risk of miscarriage associated with 
invasive prenatal tests. Based on the available results 
of the confirmation genetic tests, no misdiagnosis 
was found in this small series. 
Discussion
In 2014, the ESHRE PGD Consortium published 
data for 1597 PGD cycles from 60 PGD centres in 
Europe in 2009.7 When comparing our PGD data 
with those of the ESHRE PGD Consortium, we have 
a comparable mean number of embryos biopsied per 
oocyte retrieval cycle (6.1 vs 6.6) and similar mean 
number of embryo transfers per retrieval cycle (1.4 
vs 1.3). The ESHRE PGD Consortium reported a 
clinical pregnancy rate of 30.2% per transfer, while 
the ongoing pregnancy rate per transfer in our centre 
was 38.0% for fresh transfer and 37.5% for FET. The 
ongoing pregnancy rate per transfer in the IVF-
ICSI cycle without PGD was 36% in our centre. The 
implantation rate of PGD embryos from the ESHRE 
PGD Consortium was 21.3% and in our programme 
was 35.2% for fresh cycles and 30.0% for FET cycles. 
The implantation rate in our IVF-ICSI programme 
without PGD was 27.7%. 
 A limitation of the present study was that the 
number of cases of each genetic disease involved 
was small. Many genetic diseases had only one case 
in this cohort of patients. The usefulness of PGD in 
these cases needs to be confirmed in a larger cohort 
of patients.
 The cancellation rate for PGD after initiation 
of stimulation was 18.5% (23/124). The major reason 
for cancellation was poor response leading to a small 
number of good-quality embryos available for PGD. 
In such circumstance, cleavage-stage embryos were 
frozen and batched for the next stimulated PGD 
cycle. By increasing the number of embryos tested 
per PGD cycle, this ‘batching’ strategy increased the 
chance of having disease-free embryos for transfer. 
The strategy also enabled patients to have the best-
quality embryo chosen, instead of experiencing 
multiple cancellations of embryo transfer after PGD. 
 For those cases proceeding to PGD, 8.9% 
resulted in no embryo transfer. Embryo transfer 
was cancelled because of the risk for OHSS or no 
genetically transferable embryos available. In cases 
at risk for OHSS, good-quality blastocysts were 
vitrified for subsequent FET cycles. Some reports 
have suggested that FET cycles may result in higher 
pregnancy and implantation rates than stimulated 
cycles8-10 due to the better receptivity of the 
endometrium without gonadotropin stimulation. An 
additional benefit of FET lies in being free of risk for 
OHSS when compared with fresh embryo transfer.
 Among the 124 cycles initiated for PGD during 
the study period, alpha- and beta-thalassaemia 
(autosomal recessive disorders) accounted for 
70.2% of the PGD cases. This is due to a high 
percentage of carriers in the population in Hong 
Kong, with a prevalence of 4.5% and 2.8% for alpha-
thalassaemia (South-East Asian deletion type) and 
beta-thalassaemia, respectively.11,12 The second most 
frequent indication for PGD was neurodegenerative 
disorders such as SCA3 and HD, which are inherited 
in an autosomal dominant fashion. These conditions 
accounted for 8.9% of PGD cycles. The local 
prevalence of HD is estimated to be four per million 
population.13,14 There were 16 SCA cases diagnosed 
in three hospitals in Hong Kong within 3 years, and 
SCA3 accounted for 75% of the cases.15
 It is noteworthy that 4.8% of the PGD cases 
were for cancer predisposition. However, it is always 
controversial to offer PGD to couples with inherited 
mutations of late-onset reduced penetrance cancer 
predisposition such as breast cancer.16 Additional 
controversy lies in the fact that PGD does not 
remove all the risks associated with the disease. 
Other known risk factors involved in breast cancer 
include obesity, use of hormone therapies (progestin 
and oestrogen), increased breast tissue density, 
alcohol use, and physical inactivity.17 In 2003, the 
ESHRE Ethics Task Force published a recommended 
multidisciplinary approach to the application of PGD, 
stating that PGD for multifactorial diseases such as 
BRCA mutation is acceptable notwithstanding the 
uncertainties about the genetic predisposition and 
the epigenetic influence.18 The United Kingdom 
Human Fertilisation and Embryology Authority 
also accepted PGD for various hereditary cancer 
syndromes, including familial adenomatous 
polyposis, neurofibromatosis type 1 and type 2, and 
von Hippel–Lindau syndrome. 
 Apart from the monogenetic diseases, other 
genetic tests such as HLA typing can be done on the 
same samples. In these cases, the embryos were not 
treated differently from those without HLA typing. 
Therefore, it is unlikely that the additional test would 
affect the ongoing pregnancy rate or implantation 
rate. Without indication, aneuploidy screening 
was not performed at the same time as PGD for 
monogenetic diseases. In our series, there were two 
pregnancies complicated by aneuploidy (trisomy 21 
and trisomy 13 for each). Both patients were young 
(age, 31 years) with no previous pregnancy affected 
by aneuploidy. The usefulness of preimplantation 
aneuploidy screening in young patients is still under 
debate.
 In our centre, we always consider each case 
individually and take into account the family 
histories of the couples, especially for late-onset 
genetic diseases such as SCA3 and HD and those 
with reduced penetrance and multifactorial cancer 
predisposition such as breast cancer. Patients were 
extensively counselled by a geneticist before referral 
for PGD treatment. Informative and non-directive 
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counselling by specialists in reproductive medicine 
was also given to patients. Options other than 
PGD—such as prenatal diagnosis after becoming 
pregnant without PGD, gamete donation, embryo 
donation, adoption, or remaining childless—were 
discussed. Patients who became pregnant after PGD 
were referred to the prenatal diagnosis centre in Tsan 
Yuk Hospital for counselling. Prenatal diagnosis was 
encouraged for confirmation of the genetic status 
of the fetus. If patients refused to undergo invasive 
prenatal testing, postnatal cord blood genetic 
confirmation may be considered if the offspring 
will benefit from the early surveillance or postnatal 
treatment. When encountering controversial PGD 
cases, meetings were held to discuss the case with 
geneticists, obstetricians, specialists in prenatal 
diagnosis, ethicists, and other relevant specialists 
such as oncologists before offering PGD.
Conclusions
Preimplantation genetic diagnosis is a reliable 
method with ongoing pregnancy rate and 
implantation rate similar to those with IVF and 
ICSI. When couples have known genetic diseases, 
they should be counselled before pregnancy for 
preimplantation genetic diseases as an alternative 
to prenatal diagnosis, even when they do not have a 
previous affected pregnancy. 
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